Inicio › Cáncer de pulmón de células no pequeñas › Nuevo Hampshire
Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Nuevo Hampshire
17 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Nuevo Hampshire.
Ciudades en Nuevo Hampshire
Texto oficial del estudio (inglés)
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Dartmouth-Hitchcock Medical Center /ID# 277673, Lebanon
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT07155187Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- New Hampshire Oncology Hematology PA-Concord, Concord
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
- Solinsky Center for Cancer Care, Manchester
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT04267848Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Dartmouth-Hitchcock Medical Center, Lebanon
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06881784A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Dartmouth Hitchcock Medical Center, Lebanon
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06667076Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Dartmouth-Hitchcock Medical Center, Lebanon
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06890598Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Lebanon
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06767514A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- Dartmouth Hitchcock Medical Center, Lebanon
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT04302025A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Dartmouth Hitchcock Medical, Lebanon
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06253871A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Dartmouth-Hitchcock Medical Center, Lebanon
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06119581KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT04165798KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT04165070Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 jun 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 may 2026 · NCT06116682Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
- Solinsky Center for Cancer Care, Manchester
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT06616584Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
ReclutandoFase 2
18 Minutes · Todos los sexos · Actualizado el 5 may 2026 · NCT06031688A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- Dartmouth Hitchcock, Lebanon
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 abr 2026 · NCT06362369A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
- Dartmouth Hitchcock Medical Center, Lebanon
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 mar 2026 · NCT05948865De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.